Skip to main content
Premium Trial:

Request an Annual Quote

Compugen Shares Up Nearly 10 Percent On News of Drug Collaboration

NEW YORK, Oct. 25 (GenomeWeb News) - Shares in Compugen were up nearly 10 percent in mid-afternoon trading today as investors welcomed the company's recently announced R&D collaboration with Evogene.


Shares in the company reached a high of $4.47 earlier in the day before settling at $4.15, 9.8 percent above their close last Friday.

Terms of the agreement call for Evogene to use its Plant Made Pharmaceutical platform to evaluate the production of three of Compugen's therapeutic protein candidates. The deal also enables Evogene to validate its platform.

Currently, mammalian cell culture is the dominant method for the manufacture of biological products. But this method is complex and expensive. The use of modified plants for human protein production is gaining traction among some drug makers.


Evogene's PMP technology harvests and extracts the target protein and its subsequent purification. The platform relies on the existing machinery of a specific plant tissue that produces a high concentration of a native protein, and the plant tissue allows easy harvesting and extraction of the protein.


Financial terms of the deal were not disclosed.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.